Evidera
Venediktos Kapetanakis is an accomplished statistician specializing in health economics, outcomes research, and epidemiology. Currently serving as Senior Director of Statistics at Evidera since January 2017, Venediktos leads statistical initiatives across multiple projects, focusing on real-world data analysis and health-economic modeling. Previous positions include HEOR Statistician at DRG Abacus and Senior Research Fellow at St. George's University of London, where Venediktos contributed significantly to peer-reviewed research and interdisciplinary team coordination. Additional consulting roles have encompassed diverse sectors, including workforce equality analysis at the University of Cambridge and obesity trend modeling at the UK Health Forum. Venediktos holds a PhD in Biostatistics from the University of Cambridge and advanced degrees in Biostatistics and Applied Mathematics from the National and Kapodistrian University of Athens and the University of Crete, respectively.
This person is not in any teams
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.